Article Information
History
- February 9, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Gaspar A. Pacheco1,
- Nicolás M. S. Gálvez1,
- Catalina A. Andrade1,
- Yaneisi Vázquez1,
- Linmar Rodríguez-Guilarte1,
- Pablo A. González1,
- Susan M. Bueno1 and
- Alexis M. Kalergis1,2,*
- 1Millennium Institute of Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
- 2Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
- ↵*Corresponding author:
Dr. Alexis M. Kalergis. Full Professor and Director, Millennium Institute of Immunology and Immunotherapy, Pontificia Universidad Católica de Chile. Av. Libertador Bernardo O’Higgins 340. Email: akalergis{at}bio.puc.cl
Posted February 09, 2022.
A recombinant BCG-based vaccine against the human respiratory syncytial virus induces a balanced cellular immune response against viral and mycobacterial antigens
